---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-234991"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-05-21T22:02:43+00:00"
generated_at: "2026-05-22T10:10:53.942605+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports interim clinical data from three radiopharmaceutical programs at ASCO 2026

## Summary
- VMT01 in melanoma: 2/7 confirmed responses (29%) at 3.0 mCi; 6/7 stable disease or partial response.
- [212Pb]PSV359 advanced to Cohort 3 (6.0 mCi); no DLTs, grades 1-2 TEAEs only.
- VMT-α-NET: deepened responses vs prior cut-offs; 10/23 (43%) Cohort 2 patients achieved response per RECIST v1.1.
- All programs well-tolerated: no treatment-related discontinuations, no Grade 4/5 events across 68+ patients.

## SEC filing metadata
- accession: 0001193125-26-234991
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-05-21T22:02:43+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526234991/0001193125-26-234991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526234991/catx-20260521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-234991
- JSON: https://secwatch.observer/filing/0001193125-26-234991.json
- Plain text: https://secwatch.observer/filing/0001193125-26-234991.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.